产品
编 号：F217792
分子式：C30H42FN5O3
分子量：539.68
分子式：C30H42FN5O3
分子量：539.68
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
结构图
CAS No: 1799328-86-1
产品详情
生物活性：
Tolinapant (ASTX660) is an orally bioavailable dual antagonist of cellular inhibitor of apoptosis protein (cIAP) and X-linked inhibitor of apoptosis protein (XIAP).
体内研究：
In HCC1806 xenografts in mice, Tolinapant (daily oral treatment) causes moderate tumor growth inhibition but not regression.
体外研究：
Tolinapant is an orally bioavailable dual antagonist of cIAP and XIAP, currently being investigated in a single-agent Phase 1/2 clinical trial in patients with advanced solid tumors and lymphomas. Twenty-one triple-negative breast cancer (TNBC) cell lines are treated with Tolinapant in vitro and it is found that 43% are sensitive to Tolinapant.
Tolinapant (ASTX660) is an orally bioavailable dual antagonist of cellular inhibitor of apoptosis protein (cIAP) and X-linked inhibitor of apoptosis protein (XIAP).
体内研究：
In HCC1806 xenografts in mice, Tolinapant (daily oral treatment) causes moderate tumor growth inhibition but not regression.
体外研究：
Tolinapant is an orally bioavailable dual antagonist of cIAP and XIAP, currently being investigated in a single-agent Phase 1/2 clinical trial in patients with advanced solid tumors and lymphomas. Twenty-one triple-negative breast cancer (TNBC) cell lines are treated with Tolinapant in vitro and it is found that 43% are sensitive to Tolinapant.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备